[1] West J B. High-altitude medicine[J]. Am J Respir Crit Care, Med, 2012,186(12):1229-1237. [2] Bouchard C, Dionne F T, Simoneau J A, et al.Genetics of aerobic and anaerobic performances[J].Exerc Sport Sci Rev, 1992, 20:27-58. [3] West J B, Hackett P H, Maret K H, et al. Pulmonary gas exchange on the summit of Mount Everest[J]. J Appl Physiol: Respir, Environ Exerc Physiol,1983,55(3): 678-687. [4] Joyce K E, Lucas S J E, Imray C H E, et al. Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema[J]. Expert Opin Pharmacother, 2018,19(17):1891-1902. [5] Bartsch P, Swenson E R. Clinical practice: acute high-altitude illnesses[J]. N Engl J Med, 2013, 368(24):2294-2302. [6] Leon-Velarde F, Maggiorini M, Reeves J T, et al. Consensus statement on chronic and subacute high altitude diseases[J]. High Alt Med Biol, 2005, 6(2):147-157. [7] Grimminger J, Richter M, Tello K, et al. Thin air resulting in high pressure:mountain sickness and hypoxia-induced pulmonary hypertension[J]. Can Respir J, 2017, 2017:8381653. [8] Laddha A P, Kulkarni Y A. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders[J].Respir Med, 2019, 156:33-46. [9] Ma T T, Wang Y, Zhou X L, et al. Research on rat models of hypobaric hypoxia-induced pulmonary hypertension[J]. Eur Rev Med Pharmacol Sci,2015,19(19): 3723-3730. [10] 周晓玲, 潘磊, 姚小燕, 等. 通心络对低压低氧性肺动脉高压大鼠HIF-1α及相关因子的作用[J]. 微循环学杂志,2015,25(2): 8-11. [11] Zhao S, Xue X Y, Pan L, et al. A rat model of sustained hypobaric hypoxia-induced pulmonary hypertension[J]. Int J Clin Exp Med,2017,10(2):3366-3372. [12] 刘杰,刘川川,刘辉琦, 等. 低压低氧对SD大鼠肺动脉压及肺组织骨桥蛋白表达的影响[J].中国动脉硬化杂志,2016,24(1): 29-33. [13] Humbert M,Guignabert C,Bonnet S, et al.Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives[J].Eur Respir, 2019,53(1): 1801887. [14] 赵晟,姚小燕,薛新颖, 等. 低压低氧肺动脉高压中组织因子致高凝状态的研究[J].中国分子心脏病学杂志,2016,16(6):1920-1922. [15] Medford A R, Millar A B. Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?[J].Thorax,2006,61(7):621-626. [16] Varet J, Douglas S K, Gilmartin L, et al. VEGF in the lung: a role for novel isoforms[J]. Am J Physiol Cell Mol Physiol, 2010, 298(6):L768-774. [17] Tischer E, Mitchell R, Hartman T, et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing[J]. J Biol Chem,1991,266(18):11947-11954. [18] Shehata S M, Mooi W J, Okazaki T, et al. Enhanced expression of vascular endothelial growth factor in lungs of newborn infants with congenital diaphragmatic hernia and pulmonary hypertension[J]. Thorax,1999,54(5): 427-431. [19] Chen J, Cui X L, Li L, et al. MiR-339 inhibits proliferation of pulmonary artery smooth muscle cell by targeting FGF signaling[J]. Physiol Rep, 2017, 5(18):e13441. [20] Raines E W. PDGF and cardiovascular disease[J].Cytokine Growth Factor Rev,2004,15(4):237-254. [21] Grimminger F, Schermuly R T. PDGF receptor and its antagonists: role in treatment of PAH[J].Adv Exp Med Biol, 2010, 661: 435-446. [22] 李小静,刘川川,刘辉琦,等.低氧对大鼠血清bFGF、VEGF的表达和肺动脉超微结构的影响[J].中国高原医学与生物学杂志,2017, 38(3): 164-170. [23] 张程燕,张继新, 吕晓涛,等.间断性低氧暴露对红细胞参数及血清HIF-1α、EPO的影响[J].细胞与分子免疫学杂志,2009, 25(10): 932-934,941. |